Who
Scott Thomas Smith
EVP & Chief Financial Officer
Company insider
Files Form 4 as: EVP & Chief Financial Officer, Ascendis Pharma A/S.
In numbers
- Trades disclosed
- 4
- Buys
- 2
- Sells
- 0
- Bought
- $155K
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 29 May 2026
- Last trade
- 2 Jun 2026
- Last filed
- 2 Jun 2026
Companies traded
Activity over time
1 May – 1 Oct
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 2 Jun 2026filed 2 Jun 2026 | ASND Ascendis Pharma A/SBiotechnology | SEC FORM 4 Bought | $22K100 at $219.00 | filing |
| 2 Jun 2026filed 2 Jun 2026 | ASND Ascendis Pharma A/SBiotechnology | SEC FORM 4 Bought | $22K100 at $219.00 | filing |
| 29 May 2026filed 1 Jun 2026 | ASND Ascendis Pharma A/SBiotechnology | SEC FORM 4 Bought | $56K250 at $223.32 | filing |
| 29 May 2026filed 1 Jun 2026 | ASND Ascendis Pharma A/SBiotechnology | SEC FORM 4 Bought | $56K250 at $223.32 | filing |
News
Ascendis Pharma A/S (NASDAQ:ASND) vs. Rigel Pharmaceuticals (NASDAQ:RIGL) Head-To-Head ReviewASND · tickerreport.com · 21 Oct 2026
0 headlines in the last 90 days name Scott Thomas Smith; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.